• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Femtosecond laser-assisted cataract surgery: One physician’s story

Publication
Article
Digital EditionOphthalmology Times: October 15, 2021
Volume 46
Issue 17

Ophthalmologist outlines his journey with the procedure as a late adopter.

Ophthalmologist outlines his journey with the procedure as a late adopter.

Special to Ophthalmology Times®

My partner and I were not early adopters of femtosecond laser technology. We had been running a well-established optometric referral practice at an ambulatory surgery center for more than 30 years before we considered it. Several factors led to our decision.

As ophthalmology section chief, I noticed that many of the younger surgeons we were considering for our staff wanted to join a facility with femtosecond laser capabilities.

john c. baldinger, md

Baldinger

Second, a rival practice was performing a high volume of femtosecond laser-assisted cataract surgery (FLACS) cases.

Third, patients would call our practice to find out whether we offered FLACS. We would tell them no but assure them that our doctors have a lot of experience. However, we ended up losing patients to our competitor.

Because this technology is well adopted in most facilities, we invested in a femtosecond laser (LENSAR).

Related: Cataract surgery pearls for cases with poor mydriasis, zonules

As an experienced surgeon who has performed more than 50,000 procedures, I have a low complication rate with great results.

After performing FLACS, I realized that there are some things this technology can reproducibly do better than I can.

Immediately, I began to see tighter, more accurate, and more precise results.

The fact that I could now have a capsulorhexis and opening of exactly 5 mm and not 4.8 mm or 5.1 mm meant that, when those patients left the operating room, I knew their procedure was 100% accurate.

I also found an improvement in the softening of the lens. The chopping and dicing facilitated the nuclear lens material removal. It required less phaco energy and produced faster phaco times.

Related: Evaluating dexamethasone intraocular suspension 9% post-cataract surgery

Patients were seeing closer to 20/20 on postoperative day 1 after FLACS than they were with traditional surgery. These were clear advantages.

Occasionally, I get patients with previous trauma or who may have had retinal problems and undergone a pars plana vitrectomy. Their zonular structure and integrity of the eye are often not the same as those of a virgin eye.


Workflow

Because we do not keep the femtosecond laser in our operating room but in a clean area, I thought workflow would slow down. However, we move patients directly from the clean area to the operating room.

Related: Impact of prior authorization for cataract surgery

When the femtosecond laser is done, the operating room is being turned around and the circulator is ready to bring the patient right back because I am working out of 1 room.

The entire process from the time of docking is roughly a minute and a half.

FLACS has also improved my patient experience because I no longer do manual marking.

I use preoperative iris imaging and astigmatism diagnostics technology (Cassini Technologies) that interfaces with my femtosecond technology.

The manual marking using the Iris registration (even if I do not use the exact number from the imaging and diagnostic technology) allows me to manually enter the number and still have Iris registration.

Related: Timing and earlier neurolept anesthesia for laser-assisted cataract surgery

I have had cases where I have had a marker using any kind of mechanical device, when suddenly the patient looks up or down and ends up with a corneal abrasion, and I have not even started the case.

The fact that I no longer must mark the cornea, potentially creating a corneal abrasion and running the risk of patients complaining the next day, is huge.

The IntelliAxis L is a unique feature on our femtosecond laser platform. The femto places a little nick in the capsule at the steep axis.

When I align a toric lens, whether it is a monofocal toric or a presbyopic toric, that mark is right where the lens toric mark is. There is no parallax.

I know exactly where that lens is to be aligned. It makes the alignment much more precise and easier. We are getting 20/20 eyes at day 1 on high powered toric IOLs that we were never seeing before.

Related: What patients need to know about cataract surgery

Financial benefits
There are patients who want the technology. It is not an uphill sale. It sells itself.

Clearly, the ability to have a procedure that drops to the bottom line of the practice with a decreasing reimbursement from the federal government, Medicare, and non-

Medicare cases is a challenge. Reimbursements are going to continue to drop. We can balance-bill patients for a premium service when treating presbyopia and/or astigmatism because those are noncovered conditions.

Conclusion
There may be other surgeons like me who have many years of experience and are very happy with their outcomes.

Related: Cataract surgeons on OR waste: Less is often more

However, if they can avail themselves of femtosecond laser technology, it is worth being open-minded and giving it a shot. In the last 12 months, our premium conversion for toric and presbyopic lenses has been higher than ever.

As the penetration of premium lenses increases, FLACS will be a further catalyst to drive more business through the premium channel.


--
John C. Baldinger, MD

P: 703/876-9630
Baldinger is an ophthalmologist with Capital Eye Consultants in Fairfax, Virginia. He has no financial disclosures related to this content.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.